Could this be the end of yearly flu shots? early trial tests universal vaccine
NCT ID NCT03816878
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage study tested a 'prime-boost' approach for a universal flu vaccine. Researchers gave an inactivated H5N1 flu shot to 32 healthy adults, some of whom had previously received other experimental flu vaccines. The goal was to see if this method could trigger broad immunity against multiple flu strains. The study focused on safety and immune response, not on preventing flu itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inactivated subunit H5N1 influenza vaccine
What this could lead to
If successful, this approach could help develop a universal flu vaccine that protects against many flu strains, reducing the need for annual shots.
What could go wrong
This is a very early Phase 1 trial with only 32 participants, so results may not apply broadly. The vaccine may not produce strong enough immunity or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, 21205, United States